Drug Profile

IMB 150

Alternative Names: ALV 107; IMB-150; IMB-9011500; LYT-503; LYT-503/IMB-150

Latest Information Update: 19 Oct 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Alivio Therapeutics
Class Analgesics; Anti-inflammatories; Non-opioid analgesics
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Interstitial cystitis

Most Recent Events

19 Oct 2022 Phase-I clinical trials in Interstitial cystitis in USA (unspecified route) (Imbrium Therapeutics pipeline, October 2022)
26 Apr 2022 Alivio Therapeutics plans to file an IND application with in Interstitial cystitis, in 2022
07 Sep 2021 IMB 150 is still in preclinical development in Interstitial-cystitis in USA (PureTech Health pipeline, September 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com